Etiology, prevalence, and treatment of dry eye disease

Clinical Ophthalmology

Volumn 3, Issue 1, 2009, Pages 405-412

  Gayton, Johnny L ^a  

^a Eyesight Associates   (United States)

Author keywords

Dry eye disease; Etiology; Postmenopausal women; Prevalence

Indexed keywords

ARTIFICIAL TEAR; BRIMONIDINE; CYCLOSPORIN A; MOXIFLOXACIN; OPTIVE; REFRESH TEARS; SOOTHE; SYSTANE; TIMOLOL; TRAVATAN Z; UNCLASSIFIED DRUG;

DRY EYE; HUMAN; JAPAN; POSTMENOPAUSE; PREVALENCE; QUALITY OF LIFE; REFRACTIVE SURGERY; REVIEW; RISK FACTOR; TAIWAN; TEAR FILM;

EID: 75349093298     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s5555     Document Type: Review

References (54)

1. O'Brien PD, Collum LM. Dry eye: diagnosis and current treatment strategies. Curr Allergy Asthma Rep. 2004;4:314-319.
2. Sjögren HSC. Zur Kenntnis der Keratoconjunctivitis sicca (Keratitis filiformis bei Hypofunktion der Tränendrüsen). Acta Ophthalmol. 1933;Supp. II:1-151 Copenhagen.
3. Murube J. Andrew de Roetth (1893-1981): dacryologist who introduced the term dry eye. Ocul Surf. 2004;2:225-227.
4. Lemp MA. Report of the National Eye Institute/industry Workshop on clinical trials in dry eye. CLAO J. 1995;21:221-232.
5. International Dry Eye Workshop (DEWS). The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop. Ocul Surface. 2007;5:75-92.
6. Foulks GN. Pharmacological management of dry eye in the elderly patient. Drugs Aging. 2008;25:105-118.
7. Terry MA. Dry eye in the elderly. Drugs Aging. 2001;18:101-107.
8. Fox RI, Howell FV, Bone RC, et al. Primary Sjögren's syndrome: clinical and immunopathologic features. Semin Arthritis Rheumatol. 1984;14:77-105.
9. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol. 2008;173:600-609.
10. Schaumberg DA, Sullivan DA, Buring JE, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318-326.
11. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264-1268.
12. Lin PY, Tsai SY, Cheng CY, et al. Prevalence of dry eye among an elderly Chinese population in Taiwan: The Shihpai eye study. Ophthalmology. 2003;110:1096-1101.
13. McCarty CA, Bansal AK, Livingston PM, et al. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology. 1998;105:1114-1119.
14. Schaumberg DA, Sullivan DA, Dana MR. Epidemiology of dry eye syndrome. Adv Exp Biol Med. 2002;506:989-998.
15. Market Scope. Report on the global dry eye market. St. Louis, MO. 2004.
16. Lee AJ, Lee J, Saw S-M, et al. Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia. Br J Ophthalmol. 2002;86:1347-1351.
17. Doughty MJ, Fonn D, Richeter D, et al. A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada. Optom Vis Sci. 1997;74:624-631.
18. Shimmura S, Shimazaki J, Tsubota K. Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye. Cornea. 1999;18:408-411.
19. Perry HD, Donnenfeld ED. Dry eye diagnosis and management in 2004. Curr Opin Ophthalmol. 2004;15:229-304.
20. Isreb MA, Greiner JV, Korb DR, et al. Correlation of lipid layer thickness measurements with fluorescein tear film break-up time and Schirmer's test. Eye. 2003;17:79-83.
21. Stern ME, Beuerman RW, Fox RI, et al. A unified theory of the role of the ocular surface in dry eye. Adv Exp Med Biol. 1998;438:643-651.
22. Lambert DW, Foster CS, Perry HD. Schirmer test after topical anesthesia and the tear meniscus height in normal eyes. Arch Ophthalmol. 1979;97:1082-1085.
23. Connor CG, Flockencier LL, Hall CW. The influence of gender on the ocular surface. J Am Optom Assoc. 1999;70:182-186.
24. Krenzer KL, Dana MR, Ullman MD, et al. Effect of androgen deficiency on the human meibomian gland and ocular surface. J Clin Endocrinol Metab. 2000;85:4874-4882.
25. Schaumberg DA, Buring JE, Sullivan DA, et al. Hormone replacement therapy and dry eye syndrome. JAMA. 2001;286:2114-2119.
26. Uncu G, Avci R, Uncu Y, et al. The effects of different hormone replacement therapy regimens on tear function, intraocular pressure and lens opacity. Gynecol Endocrinol. 2006;22:501-550.
27. Smith JA, Vitale S, Reed GF, et al. Dry eye signs and symptoms in women with premature ovarian failure. Arch Ophthalmol. 2004;122: 151-156.
28. Ang RT, Dartt DA, Tsubota K. Dry eye after refractive surgery. Curr Opin Ophthalmol. 2001;12:318-322.
29. Donnenfeld ED, Ehrenhaus M, Solomon R, et al. Effect of hinge width on corneal sensation and dry eye after laser in situ keratomileusis. J Cataract Refract Surg. 2004;30:790-797.
30. Miljanović B, Trivedi KA, Dana MR, et al. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. Am J Clin Nutr. 2005;82:887-893.
31. Schlote T, Kadner G, Frudenthaler N. Marked reduction and distinct pattern of eye blinking in patients with moderately dry eyes during video display terminal use. Graefes Arch Clin Exp Ophthalmol. 2004;242:306-312.
32. Schindelar MR, Prifogle E, Ouslar GW, et al. Diurnal variations in symptoms of dry eye. ARVO April 27-May 1, Fort Lauderdale, Florida. D761. 2008.
33. Wolkoff P, Nøjaard JK, Troiano P, et al. Eye complaints in the office environment: precorneal tear film integrity influenced by eye blinking efficiency. Occup Environ Med. 2005;62:4-12.
34. Wolkoff P, Nøjaard JK, Franck C, et al. The modern office environment desiccate the eye? Indoor Air. 2006;16:258-265.
35. Kjæregaard SK, Hempel-Jørgensen A, Mølhave L, et al. Eye trigeminal sensitivity, tear film stability, and conjunctival epithelium damage in 182-non-allergic, non-smoking Danes. Indoor Air. 2004;14:200-207.
36. Wolkoff P, Kjæregaard SK. The dichotomy of relative humidity on indoor air quality. Environ Int. 2007;33:850-857.
37. Khurana AK, Choudhary R, Ahluwalia BK, et al. Hospital epidemiology of dry eye. Indian J Ophthalmol. 1991;39:55-58.
38. Miljanović B, Dana R, Sullivan DA, et al. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143:409-415.
39. Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care. 2008;14:S102-S106.
40. Schiffman RM, Walt JG, Jacobsen G, et al. Utility assessment among patients with dry eye disease. Ophthalmolmology. 2003;110: 1412-1419.
41. Calculation based on A C Nielsen data through its ScanTrack FDM + 4th Channel Service for the Dry Eye Category for the 52-week period ending 8/09/08, for the US market.
42. Wolff E. 1954. Anatomy of the eye and orbit. (4th ed., p. 20-34) New York: Blackstone Co.
43. Foulks GN. Determinants of Tear Film Stability. American Academy of Ophthalmology Annual Meeting, October 15-18, Chicago. The Castroviejo Lecture; 2005.
44. Wilson MW, Dailey RA. Eyelid malposition. In: GA Cioffi (Ed.). The Devers manual: ophthalmology for the health care professional. 1997; Baltimore: Williams & Wilkins. (p. 27-35).
45. Abelson MB, Ousler GW III, Nally LA, et al. Alternative reference values for tear film break up time in normal and dry eye populations. Adv Exp Med Biol. 2002;506:1121-1125.
46. Abelson MB. Tear substitution. In: Albert DM, Jacobiec FA, Azar DT, Editors. Principles and Practice of Ophthalmology. 2nd ed. Philadelphia: WB Saunders; 1994. p. 1055-1059.
47. Noecker RJ. Comparison of initial treatment response to tow enhanced-viscosity artificial tears. Eye Contact Lens. 2006;32: 148-152.
48. Murube J, Paterson A, Murube E. Classification of artificial tears: I. Composition and properties. Adv Exp Med Biol. 1998a;438:693-704.
49. Murube J, Murube E, Zhuo C. Classification of artificial tears: II. Additives and commercial formulas. Adv Exp Med Biol. 1998b;438: 705-715.
50. Hardten DR, Brown MJ, Pham-Vang S. Evaluation of an isotonic tear in combination with topical cyclosporine for the treatment of ocular surface disease. Curr Med Res Opin. 2007;23:2083-2091.
51. Greiner JV, Glonek T, Scaffidi R. Evaluation of the first metastable lipid emulsion on symptomatic dry eye patients. Invest Opthalmol Vis Sci. 2005;45, E-abstract 2035/B804.
52. Ousler GW, Michaelson G, Christensen MT. An evaluation of tear film break up time extension and ocular protection index scores among three marketed lubricant eye drops. Cornea. 2007;26:949-952.
53. Sall KN, Cohen SM, Christensen MT, et al. An evaluation of the efficacy of cyclosporine-based dry eye therapy when used with marketed artificial tears as a supportive therapy in dry eye. Eye Contact Lens. 2006;32:21-26.
54. Resatasis®, Package Insert. Available at: www.allergan.com/assets/ pdf/restasis-pi.pdf. Accessed November 13, 2008.